abstract: Within the context of an oocyte in vitro maturation (IVM) program for reproductive treatment, oocyte cumulus complexes (COCs) derived from follicles ,6 mm in patients with PCOS were matured in vitro. Key transcripts related to meiotic maturation (FSHR, LHCGR, EGFR, PGR) and oocyte competence (AREG, ADAMTS, HAS2, PTGS2) were quantified in cumulus cells (CCs) before and after maturation. Control CC samples were collected from PCOS and normo-ovulatory patients who had undergone conventional gonadotrophin stimulation for IVF/ICSI. Additional control samples from a non-stimulated condition were obtained ex vivo from patients undergoing ovariectomy for fertility preservation. Expression data from CCs from follicles with a diameter of ,6 mm before (IVM-CCs) and after in vitro maturation (IVM-CCs) were obtained after pooling CCs into four groups in relation to the percentage of matured (MII) oocytes obtained after 40 h of IVM (0; 40 -60; 61-80; 100% MII) and values were compared with in vivo matured controls (IVO-CCs). Genes encoding key receptors mediating meiotic resumption are expressed in human antral follicles of ,6 mm before and after IVM. The expression levels of FSHR, EGFR and PGR in CCs were significantly down-regulated in the IVO-CCs groups and in the 100% MII IVM group compared with the BM groups; all the receptors studied in the 100% MII IVM group reached an expression profile similar to that of IVO-CCs. However, after maturation in a conventional IVF/ICSI cycle, IVO-CCs from large follicles contained significantly increased levels of ADAMTS1, AREG, HAS2 and PTGS2 compared with IVM-CCs and IVM-CCs; the expression patterns for these genes in all IVMCCs were unchanged compared with IVM-CCs. In conclusion, genes encoding receptors involved in oocyte meiotic resumption appeared to be expressed in CCs of small human antral follicles. Expression levels of genes-encoding factors reflecting oocyte competence were significantly altered in IVM-CCs compared with in vivo matured oocytes from large follicles. Observed differences might be explained by the different stimulation protocols, doses of gonadotrophin or by the intrinsic differences between in vivo and in vitro maturation.
Introduction
Oocytes develop within the protective and supportive environment of the follicle where communication between the oocyte and the surrounding somatic cells is crucial during follicle development and occurs until ovulation . Oocyte maturation and the acquisition of oocyte developmental competence is a tightly regulated process involving a high number of molecular pathways directed by gonadotrophin stimuli and gonadotrophin receptors expressed in granulosa cells (GCs) and cumulus cells (CCs) .
Four key receptors have a cardinal role during the complex processes of oocyte meiotic resumption and were selected for the current study. Luteinizing hormone receptor (LHCGR) is a G-proteincoupled receptor (GPCR) that activates adenylate cyclase, resulting in an important intracellular surge of cAMP; this cAMP surge activates cAMP-dependent serine protein kinase A (PKA) to induce ovulation and luteinization of the follicles (Richards et al., 1994) . Furthermore, LHCGR stimulates the production of epidermal growth-like factors in GCs and CCs (Park et al., 2004; Freimann et al., 2005; Adriaenssens et al., 2011) . Follicle-stimulating hormone receptor (FSHR) plays an important role in the development of pre-ovulatory follicles in vivo (Macklon and Fauser, 2001) ; FSHR is a GPCR closely related to LHCGR and activates adenylate cyclase, thus mediating cAMP synthesis and resulting in PKA-activated intracellular signaling (Zeleznik et al., 2003) . The epidermal growth factor receptor (EGFR) is involved in meiotic resumption within the cumulus -oocyte complex (COC) (Lorenzo et al., 1994) . EGF ligands activate the mitogen-activated protein kinase (MAPK1/3) signal transduction pathway, which is involved in the expression of extracellular matrix genes, CC expansion and ovulation (Lorenzo et al., 2001) . Progesterone receptor (PGR) is induced after the LH surge and is immediately activated by progesterone to induce CC expansion (Hedin et al., 1987) ; PGR-knockout mice exhibit normal follicle growth and luteinization but no ovulation (Robker et al., 2000) .
It has been demonstrated that a number of genes expressed in CCs after in vivo maturation are linked to oocyte competence during conventional assisted reproduction technique (ART) (McKenzie et al., 2004; Hamel et al., 2008; Assou et al., 2010; Wathlet et al., 2011) . Four markers of oocyte competence were selected: (i) a disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS1) known to be expressed and regulated in the ovary by LHCGR and PGR (Doyle et al., 2004; Shimada et al., 2004; Richards et al., 2005) ; (ii) amphiregulin (AREG), an EGFfamily member involved in the EGF signaling network and expressed in pre-ovulatory follicles (Freimann et al., 2005; Zamah et al., 2010) ; and (iii) prostaglandin-endoperoxide synthase 2 (PTGS2) and (iv) hyaluronan synthase 2 (HAS2), which are involved in signaling and extracellular matrix formation during the ovulatory response (McKenzie et al., 2004; Russell and Robker, 2007; Adriaenssens et al., 2011; Wathlet et al., 2011) .
While in conventional ART, gonadotrophins are used to stimulate the ovary to produce many large follicles with mature oocytes in vivo, IVM aims primarily to avoid the side effects of ovarian stimulation by retrieving immature oocytes from small follicles (,12 mm) from unstimulated or minimally stimulated ovaries. However, the intrinsic developmental competence of oocytes is reduced after IVM compared with conventional ART , although this might be compensated, at least partly, in PCOS patients due to the high number of antral follicles (Son and Tan, 2010) . Nevertheless, it has recently been reported (Guzman et al., 2012) that oocytes isolated from small antral follicles with a diameter of ,6 mm can mature in vitro, support embryo development and can result in live birth. However, there is no information on the expression pattern of the genes related to meiotic resumption and maturation or linked to oocyte competence in cases where no hCG is given to prime the follicles before oocyte retrieval.
All IVM-CC samples in this study were retrieved from small antral follicles with a diameter of ,6 mm. The first aim of the study was to evaluate the expression patterns in CCs for selected genes involved in oocyte maturation and to relate these to oocyte maturation rates after IVM. Secondly, the sample sets were chosen to understand gene expression patterns between in vitro and in vivo matured oocytes, and in normo-ovulatory patients and patients with PCOS.
Materials and Methods

Patients
This study was approved by the Ethics Committee of UZ-VUB Brussel. CCs were obtained from normo-ovulatory patients (either cancer patients undergoing ovarian tissue cryopreservation or patients with fertility problems undergoing conventional ovarian stimulation with IVF/ICSI treatment) and PCOS patients who underwent either IVM or conventional IVF/ICSI were included. Overall, 39 patients undergoing 47 independent cycles were included in the study. The baseline patient characteristics are summarized in Table I .
IVM treatment protocol
The clinical and laboratory protocol for IVM treatment has previously been described (De Vos et al., 2011) . Briefly, patients received 150 IU of hMG (Menopur w , Ferring Pharmaceuticals A/S, Copenhagen, Denmark) daily for 3 consecutive days, starting on Day 3 after spontaneous menses or withdrawal bleeding. Oocyte retrieval was planned on cycle day 7 or 8 depending on the endometrial thickness (.5 mm), but before the largest follicle reached a diameter of 10 mm. No hCG trigger was administered. COCs were retrieved with a 17-gauge single lumen needle (Cook Medical, K-OPS-1230-VUB, Limerick, Ireland). During the ultrasoundguided procedure, two-dimensional diameter measurements were performed in all punctured follicles. Follicular aspirates were filtered (Falcon 1060; 70-mm mesh size, Franklin Lakes, NJ, USA). COCs were collected in a flushing medium (Origio, Måløv, Denmark). All the oocytes were at the germinal vesicle (GV) stage at the time of oocyte collection. COCs were subsequently matured for 40 h in MediCult IVM w System (Origio) supplemented with 75 mIU/ml FSH, 100 mIU/ml hCG and 10% human serum albumin (Vitrolife w , Gö teborg, Sweden). After IVM, oocytes were inseminated by ICSI as described previously (Joris et al., 1998) . Oocytes and embryos were cultured individually in 25 ml medium droplets covered with mineral oil (Vitrolife 
Conventional IVF/ICSI
Controlled ovarian stimulation (COS) was performed following a conventional long agonist protocol using HP-hMG [Menopur, Ferring Pharmaceuticals (IVO-Normo group)] or rFSH [Puregon, Organon, The Netherlands (IVO-PCOS group)] in a GnRH-antagonist protocol [with ganirelix (Orgalutran)]. Daily gonadotrophin doses ranged from 150 to 225 IU/ day for HP-hMG and from 100 to 225 IU/day for rFSH. Gonadotrophins were administered at a fixed dose for 7 -13 days, starting on cycle day 2. GnRH-antagonist administration started on cycle day 7. The trigger to induce final follicular maturation (10 000 IU hCG) was administered as soon as three follicles of at least 17 mm diameter were observed by transvaginal ultrasound, and oocytes were aspirated 36 h later. ICSI was performed as described previously (Joris et al., 1998) .
Collection of samples
The different populations of CCs collected are depicted in Fig. 1 . CCs from follicles ,6 mm before oocyte in vitro maturation (BM-CC) were collected from five unstimulated normo-ovulatory patients (BM-Normo) during ovarian tissue handling after oophorectomy and before ovarian tissue cryopreservation. Briefly, follicles from the ovary were measured, punctured ex vivo with a needle and collected in flushing medium (Origio). COCs from PCOS patients (BM-PCOS) were retrieved after transvaginal ovarian puncture. BM-CCs were collected after mechanical denudation with a pipette (Vitrolife, Gö teborg, . CCs were snap-frozen in liquid nitrogen.
For the collection of in vitro maturation CC (IVM-CC), COCs from PCOS patients were cultured in groups. CCs were collected after cumulase treatment (Origio). CCs were classified according to the oocyte maturation rate. The four categories were: all oocytes were arrested in the GV or germinal vesicle breakdown (GVBD) stage (IVM-CC 1); 40 -60% of the oocytes were mature metaphase II (MII) (IVM-CC 2); 61-80% of the oocytes were MII (IVM-CC 3) and 100% of the oocytes were mature (IVM-CC 4).
As for in vivo maturation CC (IVO-CC), CCs from follicles .15 mm were aspirated in normo-ovulatory (IVO-Normo) and PCOS patients (IVO-PCOS) undergoing conventional IVF/ICSI treatment, 36 h posthCG injection. CCs were detracted from the oocyte with ICSI cumulase (Origio) 4 h after oocyte retrieval; only CCs from MII oocytes were collected and pooled for each patient .
For each of the studied groups five or six samples were collected. Each sample was a pool of 3 -6 COCs retrieved from one patient and one independent cycle.
RNA isolation and cDNA synthesis
The protocol was described previously by Adriaenssens et al. (2010) . Briefly, total RNA was extracted from CCs using the total RNA extraction kit (RNeasy; Qiagen, Antwerp, Belgium) on the QiaCube robot (Qiagen) according to the manufacturer's instructions with minor modifications. A DNAse step was used to remove residual genomic DNA and extracted total RNA was subsequently eluted in 14 ml of RNAse-free water. Total RNA was reverse transcribed into cDNA with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Gent, Belgium) containing a blend of oligo (dT) and random primers, according to the manufacturer's instructions. Negative controls were generated by omitting the RNA or the reverse transcription enzyme. All resulting cDNA was frozen at 2808C.
Quantitative PCR
cDNA quantification by real-time PCR was performed on a LightCycler 480 apparatus (Roche Applied Science, Mannheim, Germany). PCR primer design for qPCR was performed using the universal probe library software (Roche Diagnostics) (Table II) . Primers were selected to be specific and complementary to the human sequences of FSHR, EGFR, PGR, ADAMTS1 and AREG. Primer sequences for LHCGR, PTGS2 and HAS2 have been published previously Sanchez et al., 2010) . The expression of the genes was normalized using beta 2 microglobulin (b2M) and ubiquitin (UBC). The total volume for the amplification reaction was 10 ml, containing 2 ml cDNA, 5 ml SYBR Green PCR Master Mix 2× (Roche Applied Science), 1 ml of 0.6 mM primer mix and 2 ml of nuclease-free water per sample. The amplification conditions were as follows: 10 min at 958C, followed by 50 cycles at 958C for 10 s and 608C for 30 s, followed by a melting curve. A log6 dilution series of a synthetic oligonucleotide corresponding to the amplicon sequence was included in each experiment. The number of copies for each gene within each sample was normalized with the endogenous controls. Each sample was tested in triplicate and all negative controls were as expected. All results mentioned hereafter are the normalized values.
Statistical analysis
Q-PCR results were compared using two-tailed t-test or ANOVA followed by the Tukey post-hoc test. Values were determined to be significant when P , 0.05. Two subanalyses were performed: (i) to explore the differences in gene expression between subgroups of patients classified according to their endocrine background (normo-ovulatory patients and patients with PCOS) before and after IVM and (ii) 
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Data represent the mean and standard deviation (SD) values. MII, metaphase II; PCOS, polycystic ovary syndrome; BM Normo-ovulatory, before oocyte maturation in normovulatory patients; BM PCOS, before oocyte maturation in PCOS patients; IVO PCOS, after in vivo maturation in PCOS patients; IVO Normo-ovulatory, after in vivo maturation in normo-ovulatory patients; MS, minimal stimulation; COS, controlled ovarian stimulation; (2) CC gene expression in follicles ,6 mm All analyses and graphs were generated using Graphpad Prim V4.0 (Graphpad software, CA, USA).
Results Table I summarizes the basal patient characteristics. The mean age of patients in the BM-normo group was statistically lower than that of patients in the IVO-PCOS group. Additionally, patients in the BM-normo group did not receive any ovarian stimulation, whereas patients in the BM-PCOS and IVM-CC groups received minimal ovarian stimulation with a cumulative dose of 450 IU HP-HMG per cycle. Patients from IVO-CC groups received statistically higher doses of gonadotrophins in GnRH-analog treated cycles compared with the other groups. All biological material of the study was collected in a single center and all molecular analyses were performed in one single experiment. Each experimental group contained six samples obtained from independent cycles (five samples from different patients were included in BM-Normo group). In total, CCs from 224 COCs from 39 patients in 47 independent cycles were analyzed and classified according to their maturation status. All oocytes in COCs obtained before oocyte IVM (BM-groups) were at the GV stage and the CCs were still compact. After 40 h of IVM, COCs were expanded and the maturation status was assessed; mature oocytes were microinjected with partner sperm and CCs were collected.
All CC samples contained enough total RNA to detect the endogenous controls and selected genes. Figure 2 shows the relative gene expression of the receptors under study. In CCs of MII oocytes after IVM (IVM-CC 4), the levels of FSHR, EGFR and PGR transcripts were significantly down-regulated, respectively, 7-fold (P , 0.001), 3-fold (P , 0.001) and 2.5-fold (P ¼ 0.01) compared with BM-PCOS-CC. In contrast, IVM-CC 4 LHCGR expression was 3.5-fold up-regulated compared with BM-PCOS, although this was not significant (P ¼ 0.188). Similar expression patterns were observed in CCs from in vivo matured oocytes, although the increased LHCGR expression level after in vivo oocyte maturation was statistically significant compared with the those before maturation (P , 0.001) (Fig. 2) .
Gene expression patterns of markers of oocyte competence in CCs are shown in Fig. 3 . The gene expression levels of ADAMTS1, AREG, HAS2 and PTGS2 after 40 h of IVM culture were not statistically different from those before IVM culture in any of the IVM subgroups. However, the expression levels of ADAMTS1, AREG and PTGS2 were significantly up-regulated after in vivo maturation in normo-ovulatory and PCOS patients (all P-values ,0.005). Interestingly however, the HAS2 expression was not statistically different between the IVO-PCOS and any of the IVM-CC groups, but the HAS2 expression in the IVO-Normo reached statistically higher values than those in the IVM-CC groups. COCs were cultured in groups and were classified following their divergent maturation rates (IVM-CC 1-4). Gene expression levels of FSHR, EGFR and PGR were significantly higher in CCs associated with oocytes that did not mature in vitro (IVM-CC 1) than that in CC in the IVM-CC 4 group, where all oocytes reached MII stage (P ¼ 0.003, 0.006 and 0.015 respectively). In contrast, LHCGR expression showed a trend to increase in IVM-CC4 compared with that in IVM-CC1 (P ¼ 0.196). However, ADAMTS1, AREG, HAS2 and PTGS2 expression levels did not differ significantly between IVM groups in relation to different oocyte maturation rates.
Finally, a subanalysis using a t-test was performed to explore the differences in CC gene expression between normo-ovulatory and PCOS patients before IVM and after in vivo oocyte maturation: this analysis did not reveal any statistical differences between patient types. To exclude bias that may occur as a result of the analysis of CCs from multiple treatment cycles in a single patient, we performed a subanalysis excluding patients who underwent multiple cycles from each group. This resulted in a minimal number of four patients in each group, but did not alter the statistically significant differences that had been obtained with the initial analysis, in all genes and groups studied (data not shown).
Discussion
After hCG triggering, human oocytes are able to resume meiosis, CCs start to expand and the processes leading to extrusion of the first polar body are initiated. These morphological changes are observed at 15, 22 and 35 h after hCG triggering, respectively (BomselHelmreich et al., 1987) . The cellular modifications are associated with gene expression modifications at different time points, as reported in mice and pigs (Kawashima et al., 2008; Adriaenssens et al., 2011) . In vivo, in a fully grown follicle, the LH stimulus induces Figure 2 Gene expression patterns for the receptors. BM, before maturation, IVM, in vitro maturation; IVO, in vivo matured; Normo, normo-ovulatory; PCOS, polycystic ovary syndrome. FSHR, follicle-stimulating hormone receptor; LHCGR, luteinizing hormone receptor; EGFR, epidermal growth factor receptor; PGR, progesterone receptor. IVM-CC1, cumulus cells after 40 h of IVM culture of a group where all oocytes were arrested in the GV or germinal vesicle breakdown (GVBD) stage; IVM-CC2, 40 -60% of the oocytes were mature MII; IVM-CC3, 61 -80% of the oocytes were MII; IVM-CC4, 100% of the oocytes were MII. The expression of the genes was normalized using b2M and UBC. a, b, c, ANOVA test showing a statistically significant difference between the groups (P , 0.05).
CC gene expression in follicles ,6 mm the maturation cascade in GCs and transduces this stimulus to the CCs and the oocyte. Genuine IVM treatment is without hCG triggering, because oocytes are retrieved at the GV stage with compacted CCs, and the processes of meiotic resumption, CC expansion and oocyte maturation have to be completed in vitro. Therefore, COCs cultured in vitro have to be able to mature and produce paracrine signals to allow the oocyte to resume meiosis without having been exposed to the normal physiological meiosis inducing factors in vivo (e.g. LH stimuli to mural GC, EGF-like factors and prostaglandins).
Receptors involved in oocyte maturation
An antral follicle contains two types of GCs: mural GCs and CCs; LHCGR is highly expressed in mural GCs but its expression is very low in CCs (Peng et al., 1991; Yang et al., 2005) . Recently, LHCGR was studied in mural GCs and CCs in follicles from 3 to 20 mm; they report the LHCGR expression in the mural GCs for the complete follicle diameter range; additionally, LHCGR was also expressed in IVM-CC expanded and compact after in vivo hCG priming but before IVM culture (Jeppesen et al., 2012) . Our results, obtained in a non-hCG-triggered IVM system, confirm the presence of LHCGR in human CCs derived from follicles of ,6 mm before and after IVM. Moreover, the LHCGR expression in CCs was up-regulated after in vivo maturation and a similar trend was observed in the IVM group with 100% oocyte maturation but it did not reach statistical significance. LHCGR transcript levels in CCs were not significantly different between normo-ovulatory and PCOS patients. Others have found that LHCGR gene expression in large follicle GCs and theca cells from PCOS follicles is significantly higher in PCOS patients (Jakimiuk et al., 2001) , the contradictory findings might be explained by the fact that the CCs are not the main site expression/action for LHCGR or by the limited number of patients in the current and referenced manuscript. Figure 3 Gene expression patterns for the cellular markers. BM, before maturation, IVM, in vitro maturation; IVO, in vivo matured; Normo, normo-ovulatory; PCOS, polycystic ovary syndrome. ADAMTS1, a disintegrin and metalloproteinase with thrombospondin motifs-1; AREG, amphiregulin; PTGS2, prostaglandin-endoperoxide synthase 2; HAS2, hyaluronan synthase 2. IVM-CC1, cumulus cells after 40 h of IVM culture of a group where all oocytes were arrested in the GV or GVBD stage; IVM-CC2, 40 -60% of the oocytes were mature MII; IVM-CC3, 61 -80% of the oocytes were MII; IVM-CC4, 100% of the oocytes were MII. The expression of the genes was normalized using b2M and UBC. a, b, c, ANOVA test showing a statistically significant difference between the groups (P , 0.05).
In mice, CCs do not expand in response to the LH stimulus in vitro, but they do expand in response to FSH (Eppig, 1979) ; similar results have been obtained in rats where FSH was able to induce mucification and progesterone production in CCs (Hillensjo et al., 1981) . Additionally, FSH increases intracellular cAMP, promotes maturation of EGFs and activates the tyrosine kinase cascade in CCs (Dekel and Kraicer, 1978; Prochazka et al., 2003) . Following the activation of the EGF signaling, there is phosphorylation of MAPK1/3 promoting CC expansion and meiotic activation (Park et al., 2004; Diaz et al., 2006) . Furthermore, it has been proposed that the supplementation of IVM medium with hCG is not necessary to complete oocyte maturation (Ge et al., 2008) . Our findings confirm that FSHR is expressed at higher levels compared with LHCGR in CCs before oocyte IVM. Therefore, the FSHR pathway in vitro may be the main signal transducer to achieve oocyte meiotic resumption. Regarding the kinetics during the ovulatory process, our results in IVM without hCG triggering showed that FSHR is significantly down-regulated after in vitro and in vivo maturation. Remarkably, these results are in concordance with those of an IVM system with hCG triggering (Jeppesen et al., 2012) .
The EGFR is located on the cell surface and is activated by its binding to specific ligands (EGF-like factors) and PGR expression can be induced either by LH or FSH through a cAMP-mediated pathway. It has been described that both receptors are expressed in CCs (el-Danasouri et al., 1993; Zhao et al., 2005) and our results show high expression levels for both receptors before and after oocyte IVM. Furthermore, our study demonstrates that expression levels of EGFR, FSHR and PGR in the IVM-CC 1 group (absence of oocyte maturation after 40 h of IVM culture) are not different from those before IVM (BM-groups) and are significantly higher than those in the IVM-CC 4 group (full oocyte maturation to MII stage) and in in vivo matured COCs. This relative high expression level of EGFR, FSHR and PGR may reflect the incapacity of the oocyte to mature in vitro and indicate the insensitivity of the CCs to the factors driving the initiation of meiotic progression.
Markers of oocyte competence in IVM
Overall, the efficiency of IVM is limited and oocyte developmental competence in IVM is still lower than conventional ART . Nevertheless, micro-array gene expression data in a nonhuman primate model has shown a limited number of transcripts differentially expressed between in vitro and in vivo mature oocytes (Lee et al., 2008) . Despite this, a large number of genes were shown to be differentially expressed in CCs between in vitro and in vivo maturation, and the main mis-regulated pathways were DNA replication, cell cycle, cell death and lipid metabolism, suggesting that the interaction between CCs and oocytes could be affected in IVM (Lee et al., 2011) . The current study in human CCs also suggests some differences between the CCs of in vivo and in vitro matured COCs.
Female ADAMTS-1 mouse knockouts are subfertile due to impaired ovulation, with mature oocytes remaining confined in the follicles (Mittaz et al., 2004; Shozu et al., 2005) . ADAMTS-1 is induced by the LH surge in ovulating follicles and this induction depends on the expression of the PGR gene (Doyle et al., 2004; Shimada et al., 2004; Richards et al., 2005) . PGR mouse knockouts fail to ovulate and have reduced expression levels of mRNA and proteins of ADAMTS-1 (Robker et al., 2000; Russell et al., 2003) . Our results show that PGR is expressed by all CC groups analyzed. Nevertheless, the expression of ADAMTS-1 in CCs appeared not to be regulated after IVM culture (IVM-CC), not even when oocytes were able to mature in vitro. Interestingly, the results of Yung et al. (2010) are in line with our observations, with a lower expression level of ADAMTS-1 in the mural GCs isolated from small antral follicles (,10 mm), a higher expression in larger follicles (.10 mm), but still with a lower expression level in both compared with the mural GCs of conventional IVF/ICSI patients.
EGF-like growth factors (AREG, BTC and EREG) are known to activate EGFRs in COCs, and trigger oocyte maturation and CC expansion (Park et al., 2004) . AREG plays a major role in oocyte maturation in humans (Zamah et al., 2010) . We observed low levels of AREG expression after 40 h of IVM culture, compared with AREG expression levels after in vivo oocyte maturation. Several mechanisms may underlie this observation, for example, the doses of hCG in in vitro culture are low compared with the dose of hCG administered during oocyte in vivo maturation. Furthermore, AREG has been shown to be predominantly expressed during the first stage of in vitro oocyte maturation, and its expression decreases to basal levels at the end of the maturation process (Kawashima et al., 2008) .
It has been demonstrated that PTGS2 and HAS2 are needed for CC expansion and they are related to embryo quality (McKenzie et al., 2004) . In mouse, Ptgs2 and Has2 are up-regulated in CCs at the GBVD and GV stages, respectively, and the expression of these genes drops to basal levels at the time of ovulation . However, in human IVM-CC, the expression of PTGS2 and HAS2 may display a similar profile. In order to explain the similar gene expression before and after IVM, studies evaluating the developmental transitional stages throughout the maturation period rather than extreme time points should be considered. A reduced expression of PTGS2 and HAS2 in CCs after IVM compared with CCs obtained after in vivo maturation was observed, in spite of CC expansion and mucification after IVM culture. It should be stated that the CC expansion observed in an IVM system is morphologically different from that after in vivo CC expansion . These observations might be due to alternative pathways regulated in IVM-CC compared with IVO-CC, coinciding with the differential gene expression for oocyte quality markers (Lee et al., 2011) .
All CC markers of oocyte competence analyzed in this study are involved in oocyte maturation and have previously been implicated in oocyte/embryo competence in conventional ART (McKenzie et al., 2004; Feuerstein et al., 2007; Yung et al., 2010; Zamah et al., 2010) . The results of our study reveal that these markers are expressed at significantly lower levels in CCs after IVM compared with that after in vivo oocyte maturation. Nevertheless, ADAMTS1, AREG and HAS2 expression levels increase, although not significantly, after IVM in IVM-CC4 compared with BM-PCOS, while the expression of PTGS2 decreases (P . 0.05). The absence of prostaglandin E2 (PGE2) production in vitro might compromise the maturation in IVM because PGE2 is a known up-regulator of the EGF-like family member response in human GCs (Ben-Ami et al., 2006) . Reduced expression of CC genes after IVM has also been described in the monkey model using a similar experimental approach (Lee et al., 2011) . These results could either be explained by the inability of certain receptors to respond to in vitro stimuli or by the different expression profiles of these markers during IVM. The markedly different gonadotrophin CC gene expression in follicles ,6 mm stimulation protocols between in vitro and in vivo oocyte maturation treatments may also contribute to the divergent gene expression patterns Sanchez et al., 2010; Wathlet et al., 2011) . In the IVM-CC group, low doses of gonadotrophins are used in all patients and low doses of FSH and hCG were added to the maturation medium. Additionally, IVO-CC are exposed to high doses of gonadotrophins and exacerbated cellular responses to gonadotrophin treatment might illustrate similar gene expression kinetics as described in animal models (Kawashima et al., 2008; Adriaenssens et al., 2011) . Further studies would be valuable to demonstrate the transitional kinetics of gene expression during oocyte maturation.
With regard to the patient's endocrine profile, several previously published studies have reported similar gene expression profiles. However, in patients with PCOS, a number of studies have reported altered gene expression patterns in the CCs of these patients, such as dysregulated expression of genes involved in the Wnt signaling pathway, immunological factors and extracellular matrix genes. ADAMTS-1 dysregulation has also been associated with PCOS (Jansen et al., 2004) . However, with regard to the expression patterns of the genes studied here, no statistically significant differences were observed between CCs from normo-ovulatory patients and patients with PCOS, neither before oocyte IVM nor after in vivo maturation. This observation led us to suggest that there are no gene expression differences in this specific cohort of CCs retrieved from small antral follicles, at least for the genes under study. However, further experiments should confirm this by increasing the number of genes and patients studied.
Conclusion
In the current study, we describe for the first time the expression of a number of key genes in human CCs isolated from follicles with a diameter not exceeding 6 mm in patients undergoing IVM without hCG triggering. Genes encoding receptors involved in oocyte meiotic resumption appear to be expressed in these small human antral follicles, and the relative expression levels and profiles of these genes in CCs of oocytes capable of reaching MII after IVM are similar to those observed after in vivo oocyte maturation. However, the expression profiles of ADAMTS1, AREG, PTGS2 and HAS2, genes that are induced by an ovulation trigger and reflect oocyte competence, are significantly altered after oocyte IVM, in comparison with follicles that reached full growth in vivo. Notwithstanding this observation, nearly 50% of oocytes derived from follicles ,6 mm can mature in vitro and a subset of these oocytes have been shown to result in life births (Guzman et al., 2012) . Hence, the 'classical' CC biomarkers of oocyte competence identified in conventional IVF/ICSI treatment are probably not predictive of nuclear competence in follicles that are ,6 mm of diameter in the absence of hCG triggering before oocyte retrieval.
